Drugs / LC-K76
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07389187 | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07389174 | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC-K76 | “Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period.” NCT07389187 ↗1“Participants in this arm receive oral LC-K76 combined with standard-of-care endocrine therapy.” NCT07389174 ↗ |
| Route | Oral | “Participants in this arm receive oral LC-K76 combined with standard-of-care endocrine therapy.” NCT07389174 ↗ |